(+) naloxone and epinephrine combination therapy

A cardiovascular and respiratory stimulating composition for administration to a patient in doses, the composition comprising:

• a pharmacologically effective concentration of (+)naloxone in a carrier solution;
• and
• further comprising a pharmacologically effective amount of at least one adrenergic agonist selected from the group consisting of epinephrine, isoproterenol, albuterol, aminophylline, beclomethasone, dyphylline, flunisolide, isoetharine, metaproterenol, oxtriphylline, terbutaline, theophylline, pseudoephedrine, phenylephrine, ephedrine and norepinephrine.

A cardiovascular and respiratory stimulating composition for administration to a patient in doses, the composition comprising:

• a pharmacologically effective concentration of (+)naloxone in a carrier solution;
• and
• wherein a dose is metered to deliver between about 0.1 and 6 μg/mL of (+)naloxone.

A method of alleviating breathing passageway compromise in humans, the method comprising:

• providing a carrier solution, the solution containing (+)naloxone and a pharmacologically effective concentration of at least one adrenergic agonist, the (+)naloxone and at least one agonist forming a mixture in the saline solution;
• wherein the mixture is contained in an atomizer means to direct an atomized fog of the mixture directly into at least one breathing passageway of the human;
• directing a atomized fog dose of the mixture into the at least one breathing passageway of the human.

A method of stimulating cardiovascular and respiratory output in a human during high-stress situations, the method comprising:

• delivering a pharmacologically effective dose of (+)naloxone in a carrier solution, the (+) naloxone thus creating a first composition in the saline solution.

A method of enhancing local vasoconstriction and serve as an adjuvant administered with adrenergic agonists and other pharmaceuticals in order to contain those pharmaceuticals in a high therapeutically effective concentration at their site of administration, the method comprising:

• delivering a pharmacologically effective dose of (+)naloxone in a carrier solution, the (+) naloxone thus creating a first composition in the saline solution.